- Headquarters: Newark, CA
- Founded: 1988
- cymabay.com
- pipeline: http://www.cymabay.com/pipeline.html
CBAY is currently trialing its key product candidate seladelpar. This is a potent orally active PPARδ agonist for patients with the autoimmune liver disease, primary biliary cholangitis (PBC).
- Seladelpar poses a ‘disruptive threat’ according to top Leerink analyst Joseph Schwartz. He notes that physicians are optimistic despite relatively limited interim clinical data.
- Similarly, top HC Wainwright analyst Ed Arce likes the fact that the drug has shown no serious adverse side effects and has even reduced itchy skin. He continues: “In our view, these beneficial features put seladelpar in a very favorable position over OCA [from rival Intercept Pharmaceutical] because it addresses both the efficacy and tolerability issues… we affirm our Buy rating on increased confidence in the approvability and market potential of seladelpar.”
Description
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company's product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout. MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta (PPARd). The Company has completed over five Phase I clinical studies and a Phase II clinical study for MBX-8025. MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes (T2DM), with a dual mechanism, including direct effects and indirect effects mediated by gastrointestinal hormones known as incretins on glucose-dependent insulin secretion, as well as potentially beneficial effects on islet health. The Company has completed over four Phase I clinical studies and a Phase II clinical study for MBX-2982.
Key stats and ratios
| Q3 (Sep '17) | 2016 | |
| Net profit margin | - | - |
| Operating margin | - | - |
| EBITD margin | - | - |
| Return on average assets | -53.67% | -85.43% |
| Return on average equity | -74.52% | -166.42% |
| Employees | 21 |
No comments:
Post a Comment